99 related articles for article (PubMed ID: 2515327)
1. [Immunologic evaluation in patients with lung cancer with special regard to peripheral blood natural killer cell activity and interleukin-2 productivity].
Matsuse T; Fukuchi Y; Nagase T; Suruda T; Yamaoka M; Ishida K; Harada N; Toba K; Orimo H
Nihon Ronen Igakkai Zasshi; 1989 Sep; 26(5):475-80. PubMed ID: 2515327
[TBL] [Abstract][Full Text] [Related]
2. Phenotype and function of natural killer cells in patients with bronchogenic carcinoma.
LeFever AV; Funahashi A
Cancer Res; 1991 Oct; 51(20):5596-601. PubMed ID: 1655257
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of interleukin-2 on natural killer activity in lung cancer patients.
Ito M; Suzuki H; Yamashita N; Sugiyama E; Maruyama M; Sato M; Iwata M; Yano S
Anticancer Res; 1984; 4(6):375-8. PubMed ID: 6097158
[TBL] [Abstract][Full Text] [Related]
4. Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma.
Pitchenik AE; Guffee J; Stein-Streilein J
Am Rev Respir Dis; 1987 Dec; 136(6):1327-32. PubMed ID: 3500659
[TBL] [Abstract][Full Text] [Related]
5. In vitro natural killer and lymphokine-activated killer activity in patients with bronchogenic carcinoma.
Dunlap NE; Lane VG; Cloud GA; Tilden AB
Cancer; 1990 Oct; 66(7):1499-504. PubMed ID: 1698527
[TBL] [Abstract][Full Text] [Related]
6. Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cells.
Robinson BW; Morstyn G
Cell Immunol; 1987 May; 106(2):215-22. PubMed ID: 3494538
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer cell activity in lung cancer.
LeFever A; Funahashi A
Chest; 1991 Feb; 99(2):292-7. PubMed ID: 1989785
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic cell function in bronchogenic carcinoma.
Kratikanont P; deShazo RD; Banks DE; Chapman Y
Chest; 1987 Jul; 92(1):90-4. PubMed ID: 3595254
[TBL] [Abstract][Full Text] [Related]
9. Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2.
Kariya Y; Inoue N; Kihara T; Okamoto N; Sugie K; Mori T; Uchida A
Immunol Lett; 1992 Feb; 31(3):241-5. PubMed ID: 1372283
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte subsets in bronchoalveolar lavage fluid and in circulating blood in epidermoid bronchogenic carcinoma.
Piazza G; Marchi E; Scaglione F; Montoli CC; Losi S; Scarpazza G
Respiration; 1990; 57(1):28-36. PubMed ID: 2359893
[TBL] [Abstract][Full Text] [Related]
12. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
Yarbrough WC; Weissler JC
Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)].
Xu ZY
Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):345-7. PubMed ID: 2177396
[TBL] [Abstract][Full Text] [Related]
14. Functional character and augmentation of lymphocytes in regional lymph nodes of patients with lung cancer.
Watanabe Y; Hashizume Y; Shimizu J; Yoshida M; Watanabe S; Iwa T; Sakai S; Migita S; Sato H; Murayama T
Am Rev Respir Dis; 1990 Oct; 142(4):769-74. PubMed ID: 2221581
[TBL] [Abstract][Full Text] [Related]
15. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.
Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N
Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K
Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
[TBL] [Abstract][Full Text] [Related]
18. [The unusually favorable prognosis of multiple primary bronchial carcinoma--the consequence of natural killer cell elevation and increased interleukin 2 receptor expression?].
Plat U; Plat M
Z Erkr Atmungsorgane; 1989; 172(2):150-4. PubMed ID: 2787945
[TBL] [Abstract][Full Text] [Related]
19. [Study of pulmonary T cell subsets and killer activity in lung cancer].
Zhang DX
Zhonghua Jie He He Hu Xi Za Zhi; 1990 Apr; 13(2):78-81, 126. PubMed ID: 1975773
[TBL] [Abstract][Full Text] [Related]
20. Immune reactivity in bronchogenic carcinoma and its relation to 5-year survival rate.
Watanabe Y; Shimizu J; Hashizume Y; Tsunamura Y; Yamada T; Iwa T; Sakai S; Murayama T; Koshimura S; Saito M
J Surg Oncol; 1990 Oct; 45(2):103-9. PubMed ID: 2214788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
